Indications for Antifibrinolytic Therapy^[*]

 

^* Presented at the Postgraduate Course and Workshop “Progress in Fibrinolysis”, Milan, March 6–8, 1975.

• References

• 1 Abe T, Sato A, Hazama M, and Matsumma T. 1962; Effects of epsilon aminocaproic acid in haemophilia. Lancet 2: 405.
• 2 Abbondi F. B, Hagan J. J, Philips M, and de Renzo E. C. 1959; Inhibition of plasmin, trypsin and the streptokinase-activated fibrinolytic system by epsilon-aminocaproic acid. Archives of Biochemistry and Biophysics 82: 153.
• 3 Albrechtsen O. K, and Thaysen J. H. 1955; Fibrinolytic activity in human saliva. Acta Physiologica Scandinavica 35: 138.
• 4 Alkjaersig N, Fletcher A. P, and Sherry S. 1959; Epsilon-aminocaproic acid, an inhibitor of plasminogen activation. Journal of Biological Chemistry 234: 832.
• 5 Amris C. J, and Hilden M. 1967; Inhibition of thromboplastic activity by trasylol. Scandinavian Journal of Haematology 4: 3.
• 6 Andersson L. 1962 Studies in fibrinolysis in urinary tract disease and its treatment with epsilon aminocaproic acid. Acta Chirurgica Scandinavica. Suppl., 301.
• 7 Andersson L, and Nilsson I. M. 1961; Effect of E-amino-n-caproic acid (EACA) on fibrinolysis and bleeding conditions in prostatic disease. Acta Chirurgica Scandinavica 121: 291.
• 8 Andersson L, Nilsson I. M, Colleen S, Cranstrand B, and Melander B. 1968; Hole of urokinase and tissue activator in sustaining bleeding and the management thereof with EACA and AMCA. Annals of New York Academy of Sciences 146: 642.
• 9 Barkhan P. 1964; Haematuria in a haemophiliac treated with E-aminocaproic acid. Lancet 2: 1061.
• 10 Basu H. K. 1971; Postpartum coagulation failure. British Medical Journal 3: 251.
• 11 Biggs R, Macfarlane R. G, and Pilling J. 1947; Lancet 1: 402.
• 12 Blombäck B, Blombäck M, and Olson P. 1967; Action of a proteolytic enzyme inhibitor on blood coagulation in vitro . Thrombosis et Diathesis Haemorrhagica 18: 190.
• 13 Callender S. T, Warner G. T, and Cope E. 1970; Treatment of monorrhagia with tranexamic acid. A double-blind trial. British Medical Journal 4: 214.
• 14 Collen D, Tytgat D, Claeys H, and Piessens R. 1972; Metabolism of plasminogen in healthy subjects: effect of tranexamic acid. Journal of Clinical Investigation 51: 1310.
• 15 Cooksey M. W, Perry C. B, and Raper A. B. 1966; Epsilon-aminocaproic acid therapy for dental extractions in haemophiliacs. British Medical Journal 2: 1633.
• 16 Cox H. T, Poller L, and Thomson J. M. 1967; Gastric fibrinolysis. A possible link with peptic ulcer. Lancet 1: 1300.
• 17 Davidson J. F, McNicol G. P, Frank G. L, Anderson T. J, and Douglas A. S. 1969; Plasminogen-activator-producing tumour. British Medical Journal 1: 88.
• 18 Dubber A. H. C, McNicol G. P, Uttley D, and Douglas A. S. 1968; In vitro and in vivo studies with Trasylol, an anticoagulant and a fibrinolytic inhibitor. British Journal of Haematology 14: 31.
• 19 Egeblad K. 1966; Effects of Epsilon-aminocaproic acid on fibrin clot lysis. Thrombosis et Diathesis Haemorrhagica 15: 173.
• 20 Fletcher A. P, Alkjaersig N, and Sherry S. 1962; Fibrinolytic mechanisms and the development of thrombolytic therapy. American Journal of Medicine 33: 738.
• 21 Forbes C. D, Barr R. D, Reid G, Thomson C, Prentice C. R. M, McNicol G. P, and Douglas A. S. 1972; Tranexamic acid in control of haemorrhage after dental extraction in haemophilia and Christmas disease. British Medical Journal 1: 311.
• 22 Giordano N. D, Watkins R. S, Radivoyevitch M, and Goodsitt E. 1967; Dental extractions in haemophilic patients on aminocaproic acid prophylaxis. Oral Surgery, Oral Medicine and Oral Pathology 24: 171.
• 23 Gobbi F. 1967; Use and misuse of aminocaproic acid. Lancet 2: 472.
• 24 Gordon A. M, McNicol G. P, Dubber A. H. C, McDonald G. A, and Douglas A. S. 1965; Clinical trials of epsilon aminocaproic acid in haemophilia. British Medical Journal 1: 1632.
• 25 Grossi C. E, Moreno A. H, and Rousselot L. M. 1961; Studies on spontaneous fibrinolytic activity in patients with cirrhosis of the liver and its inhibition by epsilon aminocaproic acid. Annals of Surgery 153: 383.
• 26 Grossi C. E, Rousselot L. M, and Panke W. 1964; Control of fibrinolysis during portocaval shunts. Journal of the American Medical Association 187: 1005.
• 27 Hilgartner M. W. 1966; Intrarenal obstruction in haemophilia. Lancet 1: 486.
• 28 Johnson A. L, Skoza L, and Claus E. 1962; Observations on epsilon aminocaproic acid. Thrombosis et Diathesis Haemorrhagica 7: 203.
• 29 Konttinen Y. P. 1968. Fibrinolysis: Chemistry, Physiology, Pathology and Clinics Star. Tampere, Finland:
• 30 Kullander S, and Nilsson I. M. 1970; Human placental transfer of an anti-fibrinolytic agent (AMCA). Acta obstetrica Gynecologica Scandinavica 49: 241.
• 31 Kwaan H. C, Cocco A, and Mendeloff A. I. 1964; Histologic demonstration of plasminogen activation in rectal bopsies from patients with active ulcerative colitis. Journal of Laboratory and Clinical Medicine 64: 877.
• 32 Locksley H. B. 1966; Report on the co-operative study of intracranial aneurysms and subarachnoid hemorrhage. Section Y., Part II. Journal of Neurosurgery 25: 321.
• 33 Lucas O. N, Carroll R. T, Finkelmann A, and Tocantins L. M. 1962; Thrombosis et Diathesis. Haemorrhagica 8: 209.
• 34 McKay D. G, and Müller-Berghaus G. 1967; Therapeutic implications of disseminated intravascular coagulation. American Journal of Cardiology 20: 392.
• 35 McNicol G. P. 1962; Disordered fibrinolytic activity and its control. Scottish Medical Journal 7: 266.
• 36 McNicol G. P, Alkjaersig N, Fletcher A. P, and Sherry S. 1961; Use of epsilon aminocaproic acid in management of postoperative haematuria. Journal of Urology 86: 829.
• 37 McNicol G. P, and Douglas A. S. 1972. Thrombolytic therapy and fibrinolytic inhibitors. In: Biggs R. (ed.) Human Blood Coagulation, Haemostasis and Thrombosis. Blackwell; Oxford:
• 38 McNicol G. P, Fletcher A. P, Alkjaersig N, and Sherry S. 1962; The absorption, distribution and excretion of epsilon aminocaproic acid (EACA) following its oral or intravenous administration to man. Journal of Laboratory and Clinical Medicine 58: 15.
• 39 Markwardt F, Klocking H. P, and Landmann H. 1967; Vergleichende Untersuchungen über Antifibrinolytika. Thrombosis et Diathesis Haemorrhagica 15: 561.
• 40 Moltke P. 1958; Plasminogen activators in animal meninges. Proceedings of the Society of Experimental Biology and Medicine 98: 377.
• 41 Naeye R. L. 1962; Thrombotic state after a haemorrhagic diathesis, a possible complication of therapy with epsilon-aminocaproic acid. Blood 19: 694.
• 42 Nilsson I. M, Andersson L, and Björkman S. E. 1966 Epsilon-aminocaproic acid (EACA) as a therapeutic agent. Based on 5 years clinical experience. Acta Medica Scandinavica. suppl. 448.
• 43 Nilsson I. M, Björkman S. E, and Andersson L. 1961; Clinical experiences with ε-aminocaproic acid (EACA) as an antifibrinolytic agent. Acta Medica Scandinavica 170: 487.
• 44 Nilsson L, and Rybo G. 1967; Treatment of menorrhagia with an antifibrinolytic agent, tranexamic acid (AMCA). Acta Obstetrica Gynecologica Scandinavica 46: 572.
• 45 Okamoto S, and Okamoto U. 1962; Aminomethylcyclohexane carboxylic acid, a new potent inhibitor of fibrinolysis. Keio Journal of Medicine 11: 105.
• 46 Porter J. M, Acinapura A. J, Kapp J. P, and Silver D. 1966; Fibrinolytic activity of the spinal fluid and meninges. Surgical Forum 17: 425.
• 47 Poulain M, and Josso F. 1966 Current studies in haemophilia. Proceedings of 3rd Congress World Federation of Haemophilia, Paris. Bibl. haemat. vol. 26, p. 115. Basel and New York.
• 48 Prentice C. R. M, Lindsay R. M, Barr R. D, Forbes C. D, Kennedy A. C, McNicol G. P, and Douglas A. S. 1971; Renal complications in haemophilia and Christmas disease. Quarterly Journal of Medicine 40: 47.
• 49 Prentice C. R. M, McNicol G. P, and Douglas A. S. 1970; Studies on the anticoagulant action of Aprotinin (Trasylol). Thrombosis et Diathesis Haemorrhagica 14: 265.
• 50 Ratnoff O. D. 1961; Studies on the activation of Hageman factor. Evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent. Journal of Clinical Investigation 40: 803.
• 51 Ratnoff O. D. 1969; Epsilon aminocaproic acid – a dangerous weapon. New England Journal of Medicine 280: 1124.
• 52 Reid W. O, Hodge S. M, and Cerutti E. R. 1967; The use of EACA in preventing or reducing haemorrhages in the haemophiliac. Thrombosis et Diathesis Haemorrhagica 18: 179.
• 53 Reid W. O, Lucas O. N, Francisco J, and Geisler P. H. 1964; The use of epsilon aminocaproic acid in the management of dental extractions in the haemophiliac. American Journal of the Medical Sciences 248: 184.
• 54 Rybo G. 1966; Plasminogen activators in the endometrium. Clinical aspects. Acta Obstetrica Gynecologica Scandinavica 45: 429.
• 55 Sack E, Spaet T. H, Gentile R. L, and Hudson P. B. 1962; Reduction of prostatectomy bleeding by epsilon aminocaproic acid. New England Journal of Medicine 266: 541.
• 56 Sato S, Ishibashi Y, Endo T, Watanabe T, and Nakajima K. 1959; Clinical use of epsilon-amino-n-caproic acid in metropathia haemorrhagica. Keio Journal of Medicine 8: 267.
• 57 Stark S. N, White J. G, Langer L, and Krivit W. 1965; Epsilon aminocaproic acid therapy as a cause of intrarenal obstruction in haematuria of haemophilia. Scandinavian Journal of Haematology 2: 99.
• 58 Steichele D. F, and Herschlein H. J. 1961; Zur antifibrinolytischen Wirkung des Trypsin-Kallikrein-Inaktivators. Medizinische Welt 42: 2170.
• 59 Steiger B, White J. G, and Krivit W. 1962; Epsilon-aminocaproic acid for hematuria in hemophilia. Lancet 82: 421.
• 60 Sultan Y, Larrieu M. J, Meyer D, Caen J, and Bernard J. 1966 Current studies in haemophilia. Proceedings of 3rd Congress World Federation of Haemophilia, Paris, Bibl. haemat., vol. 26, p. 100. Basel and New York.
• 61 Tavenner B. W. H. 1968; Epsilon aminocaproic acid in the treatment of haemophilia and Christmas disease with special reference to the extraction of teeth. British Dental Journal 124: 19.
• 62 Tovi D. 1972 Studies on fibrinolysis in the central nervous system with special reference to intracranial haemorrhages and to the effect of antifibrinolytic drugs. Umea University Medical Dissertations. No. 8.
• 63 Tsevrenis H, and Mandelaki H. 1965; Haematuria in a haemophiliac treated with ε-aminocaproic acid. Lancet 1: 610.
• 64 van Itterbreek H, Vermylen J, and Verstraete M. 1968; High obstruction of urine flow as a complication of the treatment with fibrinolysis inhibitors of haematuria in haemophiliacs. Acta haematologca 39: 237.
• 65 Vinnicombe J, and Shuttleworth K.E.D. 1966; a Aminocaproic acid in the control of haemorrhage after prostatectomy. Safety of aminocaproic acid – a controlled trial. Lancet 1: 232.
• 66 Vinnicombe J, and Shuttleworth K. E. D. 1966; b Aminocaproic acid in the control of haemorrhage after prostactectomy. A controlled trial. Lancet 1: 230.
• 67 Walsh P. N, Rizza C. R, Matthews J. M, Eipe J, Kernoff P. B. A, Coles M. D, Bloom A. L, Kaufman B. M, Beck P, Hanan C. M, and Biggs B. 1971; Epsilon-aminocaproic acid bherapy for dental extractions in haemophilia and Christmas disease. A double blind controlled trial. British Journal of Haematology 20: 463.
• 68 Wright F. W, Matthews J. M, and Brock L. G. 1971; Complications of hemophilic disorders affecting the renal tract. Radiology 98: 571.